82 results about "Drug group" patented technology

The invention discloses an intestine-moistening health tea with the functions of strengthening the body, nourishing the vigour, moistening the intestines and relieving the constipation; the intestine-moistening health tea comprises drugs that: a drug group of tonifying qi: radix astragali, radix codonopsis pilosulae, largehead atractylodes rhizome, Indian buead and licorice root; a drug group of tonifying the blood: Szechuan lovage rhizome, angelic, white paeony root, rehmanniae praeparatum, rehmannia glutinosa; a drug group of invigorating yang: suncured ginseng, desertliving cistanche, herba cynomorii, meat of nut, Chinese magnoliavine fruit and dioscorea root; a drug group of nourishing yin: rhizoma polygonati, fragrant solomonseal rhizome, common macrocarpium fruit, dwarf lilyturf tuber, gemeiner bocksdorn and figwort root; a group of activating blood, dissolving stasis and activating collateral flow: root of red rooted salvia, achyranthes root, dipsacus root, malaytea scurfpea fruit, red dates, seminis coicis and lotus embryo; after the combination of the five drugs is taken, the yin and yang in the body can be balanced, the qi and blood can be harmonized and the meridians can be smooth; the body-building functions of moistening the intestines, relieving the constipation, strengthening the body and nourishing the vigour can be realized by being matched with cassia seed, Caibuzi and senna leaf; the intestine-moistening health tea has the advantages of containing no rhubarb ingredients and can be used for curing chronic constipation; the synergistic effect of each ingredients has the effect of protecting the intestines and the stomach.

The invention discloses a method and a system for predicting a drug-target protein interaction relationship based on a decision template. Multiple similarity characteristic combinations are formed in combination with existing drug compound molecular structure similarity, drug ATC annotation similarity, target protein sequence similarity and function similarity through proposing two new target protein similarity measurement policies, namely, GO ontology annotation-based and pathway function mapping-based similarity measurement; and the drug-target protein interaction relationship is predicted by adopting a KNN classification algorithm based on a hypothesis that similar drugs easily interact with similar target proteins. According to the method and the system, a decision template fusion-based policy is proposed; multiple similarity measurement-based classifier prediction results are subjected to decision level fusion; the problem that a known drug-target protein interaction relationship is relatively sparse is effectively solved in combination with concepts of super target proteomes and super drug groups; the prediction precision is improved; and the method and the system can be used for realizing target protein prediction of new drugs or drug prediction of new target proteins.

The invention provides an organizational overlapping core drug group discovery method based on complex network community discovery, which comprises the following steps: 1) the construction of a traditional Chinese medical formula (TCMF) network: a) the appear contribution (AC) of each drug in a given amount of formula is calculated, and the drugs of which the AC is smaller than a certain threshold value are deleted; b) AC values of two-tuple components are calculated to be cut, and then AC values of triple drugs are calculated to be cut; c) the TCMF network is constructed by using the rest triple drugs; d) the step 1) is completed; and 2) organizational overlapping core drug group discovery of the TCMF network: a) the TCMF network obtained in the step 1) is pre-processed; b) a max clique growing algorithm (MAIGA) is executed on the pre-processed TCMF network, so as to discover drug groups; c) a drug group division result is returned; and d) the step 2) is completed. The organizational overlapping core drug group discovery method explores the compatibility law of the TCMF a viewpoint of complex network, provides a new model for the research of TCMF mining, and solves the problem of traditional single distribution of a cluster.

The present invention relates to an analysis method for a neuron injury related differentially expressed protein. The method comprises: 1, constructing a zebrafish brain and central nerve injury model, and grouping; 2, carrying out drug treatment on the drug group; 3, extracting the total protein in each group; 4, loading the sample onto a mass spectrometer, and analyzing; and 5, carrying out bioinformatics analysis.

The invention discloses an automatic drug vending machine and a drug sorting method thereof. The automatic drug vending machine comprises a stander, a plurality of drug separating groups and a controlmodule, wherein the drug separating groups are arranged at the stander in a layering manner and comprise multiple drug separating structures which are arranged in parallel; and conveying assemblies are arranged at drug discharging ends of the drug separating structures. The drug separating groups including multiple drug separating structures are arranged on the stander, and the drug vending condition is controlled by virtue of the control module, a server and a mobile terminal. The automatic drug vending machine is simple in structure, high in degree of automation, convenient and rapid, and drugs can be accurately discharged.

The invention provides a water-soluble amino acid segmented copolymer, and a preparation method and application thereof. The amino acid segmented copolymer has the structure shown as a formula I or formula II shown as the accompanying drawing; R1 is a hydrogen, an alkyl group or a substituted alkyl group; R2 is -NH- or R5(CH2)rNH-; R3 is one or a plurality of groups of a hydrogen, a hydrophobic group and an active drug group; R4 is benzyl, cholesterol formylm, acetyl, a cholic acid group, a deoxidized cholic acid group or C4-C20 alkyl groups. The amino acid segmented copolymer is a polypeptide copolymer with excellent water solubility, and can be used in the field of delivery of biological materials such as drug. After freeze-drying, the material has a good re-dissolving effect; the defect of poor water solubility of macromolecule materials or macromolecule nanometer drug in the prior art can be overcome. The material contains the hydrophobic group through modification or is chemically bonded with drug with biological activity; the modified macromolecule material or the bonded drug can still maintain excellent water solubility and re-dissolving capability; the potential application prospect is realized in the field of biological materials.

The invention relates to a group of micro RNA related to a BafilomycinA1 liver cancer and ovarian cancer inhibition cell line, belonging to the technical field of medical biology. The preparation method comprises the following steps: respectively acting BafilomycinA1 on a liver cancer cell line BEL-7402 and an ovarian cancer cell line HO-8910, and detecting the in-vitro growth inhibition, apoptosis promoting and invasion inhibition effects of BafilomycinA1 on two cells by performing soft agar cloning formation assay, electron microscopy observation, apoptosis related enzyme detection and in-vitro invasion assay; respectively acting 400nM BafilomycinA1 on the liver cancer cell line BEL-7402 and the ovarian cancer cell line HO-8910 for 48 hours, collecting dosing cells and control cells, extracting the RNA, analyzing the high-flux micro RNA between the drug group and the control group by using Affymetrix GeneChip Human Gene Array micro RNA array, and verifying the differences of the micro RNA by using qPCR, thereby obtaining co-sensitive micro RNA of the two cells. According to the group of micro RNA sensitive to the BafilomycinA1, on one hand, the micro RNA has the cancer inhibition effectiveness corresponding to the BafilomycinA1; on the other hand, the micro RNA has obvious change in two tumor cells, and a basis is provided for targets designed by taking the micro RNA as a potential broad spectrum anti-cancer drug.

The invention provides a multi-triangular group similarity cohesion based overlapping community discovery method applicable to a TCMF network. The method comprises the following steps of: 1) a stage of finding initial communities: a. finding a central point and initializing the communities; b. searching for multiple triangular groups and adding the triangular groups to the initial communities; c. repeating the steps until the degree of the central point is less than a threshold value; d. adding undistributed nodes to the initial communities; e. ending; 2) a stage of combining the initial communities: a. calculating the similarity between every two communities; b. selecting two most similar communities to be combined; and c. repeating the steps until the end. The multi-triangular group similarity cohesion based overlapping community discovery method is applicable to the TCMF network, and the accuracy of community division is greatly improved by using a multi-triangular technology, so that structure information of drug group communities can be accurately found from the TCMF network.

The invention discloses an intelligent big data analysis method for drug group purchase, and the method comprises the steps: carrying out the standardization processing of obtained drug purchase data, and matching and associating the classification information of all drugs; constructing a functional model, and forming a multifunctional comprehensive big data model through cross correlation of common dimensions; enabling a visual intelligent analysis platform to issue contents and indexes of the functional model through the cloud according to the application scene and the user permission. The invention further provides an intelligent big data analysis system for drug group purchase. According to the invention, the intelligent big data analysis system for drug group purchase is established, so that the supervision department can be assisted in mastering the purchase condition of a medical institution, a GPO catalog, national collection and national chat, prevention and control of stored drugs and decrease and saving of the purchase amount of drugs with various classification attributes in real time, and the supervision department can be helped to better manage and control the purchase behavior, and the medical insurance fund can be better utilized.

The invention discloses an evaluation method for the improvement effect of a traditional Chinese medicine component on an azithromycin action baseline, and applications of the evaluation method in evaluation of a Fukeqianjin prescription. According to the present invention, a baseline equal addition method is used, wherein the action level of the exact and effective treatment drug azithromycin is determined, the azithromycin and a tested traditional Chinese medicine composition are administered to experiment models in a parallel manner, the baseline level of the combination medication and the treatment effect trend of the of the combination medication are determined, a group pharmacokinetics-group pharmacodynamics combined model is established, and verification is performed; the pharmacokinetics-pharmacodynamics system variation dynamics system capable of quantitatively evaluating the participation of the medicinal guide is scientifically designed, and the disadvantage of the application of the weak efficacy drug treatment effect index point method to determine mean value comparison in the research method is changed; with the application of the evaluation method of the present invention in the evaluation of the improvement of the Fukeqianjin prescription, the synergetic effect of the Fukeqianjin prescription composition on each pharmacokinetic parameter of the azithromycin can be defined, and the main drug group providing effects of anti-inflammation and blood circulation activating in the Fukeqianjin prescription composition can be summarized and obtained; and the evaluation method can be well used for evaluating the safety and the effectiveness of the combination of the traditional Chinese medicine composition and the antibiotics, particularly for evaluating the internal elimination effect of the angelica sinensis component medicinal guide in the Fukeqianjin prescription.

The invention belongs to the field of nuclear medicine, and relates to a double-enzyme system probe and application thereof. The probe has a structure shown as a formula I, and QD is a fluorophore ora drug group; L is a linker and has a structure as shown in a formula II; T is a PSMA specific targeting group; and Z is H, a nuclide chelating group, radionuclide or a nuclide chelating group chelated with radionuclide. The double-enzyme system nuclear medical probe for delivering drug molecules based on prostate specific membrane antigen PSMA targeting and Caspase-3 recognition strategies can target prostate cancer to perform radiotherapy sensitization treatment, is beneficial to solving the problems of radiotherapy resistance, targeted nuclide treatment resistance and the like of castration-resistant prostate cancer patients, and is expected to realize navigation in prostate cancer surgery. More efficient tools are provided for detection and treatment of tumor treatment, and wide application prospects are achieved.

The invention discloses an active targeting response type polypeptide drug. The active targeting response type polypeptide drug is formed by sequentially connecting an active targeting peptide fragment, a response type fragment and a small molecular drug group. The active target response type polypeptide drug has the characteristic of high specificity response to overexpressed enzymes and molecules of a tumor site, the effective concentration of a focus site is remarkably improved through drug release after response, the active target response type polypeptide drug can stay in a response region for a long time, and the active target response type polypeptide drug has great significance in long-time treatment and application research of the tumor site.

The invention relates to an FM-N-DNN-based drug and target interaction prediction method. The method comprises the following steps of: S1, obtaining drug and target interaction pairs from a DrugBank database and marking the drug and target interaction pairs as a positive samples; S2, dividing the drug and target interaction pairs into different drugs and targets and then forming an independent drug group and an independent target group; randomly selecting drugs and targets from the drug group and the target group to construct new drug and target interaction pairs, and marking samples which arenot positive samples in the newly constructed drug and target interaction pairs as negative samples; S3, extracting feature vectors of the positive samples and the negative samples by utilizing an open source python software package PyDPI; S4, preprocessing the feature vectors extracted in the step S3; S5, constructing an FM-N-DNN model and training the FM-N-FNN model by utilizing the feature vectors of the positive samples and the negative samples; and S6, predicting a drug and target interaction by utilizing the trained FM-N-DNN model.

The invention discloses a method for producing a chiral drug. The chiral drug is subjected to mixed reaction. According to the synthesis of the chiral drug, drug components for synthesizing the chiral drug are divided into a plurality of drug groups, each drug group is mixed, then mixing is performed among reaction kettles; after the mixed reaction is complete, crystallization and drying are carried out through a crystallization drying device, multiple procedures are completed in the same equipment; after drying is finished, along with discharging of crystals, the grain size of the crystals is controlled through a crystallization grinding and discharging device, and the crystals are collected; and due to the fact that discharged materials of the crystallization drying device are directly discharged into the crystallization grinding and discharging device, discharging and grinding directly act and are continuously carried out, and production procedures are reduced. The production process of the chiral drug is simplified, the production efficiency of the chiral drug is improved, and the investment of funds and personnel is reduced. The method of the invention is suitable for the technical field of chiral drug production equipment.

The invention discloses application of pyrroloquinoline quinone to the bone marrow hemopoietic function after recovery of radiation, in particular application of the pyrroloquinoline quinone (PQQ) or a pharmaceutically acceptable salt or ester of the pyrroloquinoline quinine or a medicinal composition containing either salt or ester to preparing drugs for treating bone marrow hemopoietic damage. The tested drug PQQ can be administrated with a certain promoting effect on the recovery of white blood cells, thus being beneficial to the elimination of damaged erythropoiesis factors and the recovery of reticulocytes ratio. A tested drug group and a positive drug group are higher than a contrast group in the number of bone marrow cells, and tend to increase in bone marrow DNA (deoxyribonucleic acid) content. As indicated, the PQQ can promote the recovery of bone marrow hemopoietic function.

The invention belongs to the technical field of food, and particularly relates to a Chinese medicinal composition for treating diabetes. The Chinese medicinal composition is prepared from rhizoma dioscoreae, bombyx batryticatus, radix astragali seu hedysari, poria cocos, endothelium corneum gigeriae galli, radix scutellariae, pollen typhae, herba circii aponici, flos sophorae, radix panacis quinquefolii, cornu bubali, rhizoma polygonati, radix aconiti carmichaeli, rhizoma chuanxiong, radix salviae miltiorrhizae, radix paeoniae alba, pberetima, radix notoginseng, cortex cinnamomi, rhizoma polygonati odorati, cortex eucommiae, radix ophiopogonis, rhizoma gastrodiae, herba dendrobii and trypsin. The Chinese medicinal composition for treating diabetes, which is disclosed by the invention, notonly can have an obvious effect of reducing fasting blood glucose, an area under the curve of blood glucose and indexes of cholesterol and triglyceride of a patient with the II type diabetes, is equivalent to a positive drug group in effect and is slightly superior to the positive drug group in partial index. Moreover, by a syndrome differentiation and treatment method and through adopting comprehensive measures, clinical symptoms of patients with diabetes are relieved, various complications of the diabetes are prevented and treated, a treatment effect is obvious, and the Chinese medicinal composition can implement treatment on both symptoms and root causes, is safe and reliable and has no any toxic or side effect.

The invention discloses a composition capable of lowering sugar and fat. The composition comprises the following components by weight percent: 26%-30% of an astragalus membranaceus water extract, 8%-12% of a kudzuvine root alcohol extract, 13%-17% of American ginseng powder, 14%-18% of bitter gourd powder, 0.08%-0.12% of an eclipta alcohol extract, 0.0015%-0.0020% of chromium-rich yeast and the balance being food acceptable auxiliary materials. The composition has a remarkable effect on lowering indexes of fasting blood glucose value, area under the curve of glucose, cholesterol and triglyceride of II-type diabetes patients, is equivalent to a positive drug group in effect, is superior to a positive drug group in part of the indexes, and is safe, reliable and small in side effect.

A computer-implemented drug evaluation method and system provides for evaluating safety of a drug or a drug group by performing certain computations associated with gene sequence variation informationof individuals within a population. The system calculates various scores for individual within a population and ultimately combines the scores in determining safety of the drug across the population.The drug evaluation method and a system can further be configured for identifying individuals having a high-risk of side effects to a drug or a drug group. The drug evaluation provides universal drugsafety information based on gene sequence variation information without the need to identify specific genetic markers for each drug.

There is provided a novel chain-end functionalized PEO of formulas (I) to (IV) prepared via living anionic polymerization and chain-end functionalization, as well as a simple method of preparing nano-sized transition metal or metal salt particles using the same, which can be readily stabilized even in an aqueous medium. The water-soluble PEO-based polymers having various functional groups (including a drug group such as vitamin and anti-cancer agent) and the process of preparing nano-sized transition metal or metal salt particles using the same can be advantageously used in the development of new materials for drug delivering system and imaging, e.g., a contrast agent and an anti-cancer agent simultaneously.

The embodiment of the invention provides a drug group mining method and device of a target disease, electronic equipment and a storage medium, and relates to the technical field of artificial intelligence. The drug group mining method for the target disease comprises the following steps: acquiring target medical data of the target disease; performing vector conversion processing on the drug group data to obtain a drug group vector; obtaining a target sentence vector according to the prescription data and the drug group vector; obtaining hospitalization duration frequency classification data according to the medication frequency data; obtaining clustering parameter information according to the hospitalization duration frequency classification data, and performing clustering processing on the target sentence vector to obtain clustering result data; carrying out survival analysis processing according to the clustering result data to obtain survival curve information; and performing drug mining processing from the drug group data according to the survival curve information to obtain a target drug group mining result for the target disease, and through the technical scheme provided by the embodiment of the invention, the effectiveness of the drug mining result can be improved.

The invention discloses a drug composition which comprises a first drug group, a second drug group and a third drug group. The first drug group is composed of fig leaf, non-fruiting fig leaf and Delonix regia leaf, the second drug group is non-fruiting fig leaf, and the third drug group is composed of fig fruit and pig intestines. The invention further discloses a preparation method and application of the drug composition. The drug composition can be used for treating hemorrhoids and enteritis.

The invention belongs to the technical field of transfer boxes, and discloses a special intravenous injection drug transfer box for an intravenous drug use configuration center. The special intravenous injection drug transfer box comprises a multi-layer box body and a box cover, the upper ends and the lower ends of both sides of the box body integrally form mutually matched buckles, and a handle is connected to the middle of the box cover in a bolted mode. Two parallel detachable soft clamps are connected into the box body in a clamped mode, and buckles matched with the upper side of the box body are separately and integrally formed on both sides of the box cover. According to the special intravenous injection drug transfer box for the intravenous drug use configuration center, liquid leakage of drugs caused by collision of a piston can be avoided and mutual contamination of syringes due to moving contact can be avoided, the number of drug groups can be directly counted without openingthe cover during transportation and handover, all components are detachable, and thorough cleaning and disinfection are facilitated.

The invention discloses a traditional Chinese medicine compound Tenghuanglin for preventing and treating microwave irradiation and electromagnetic pollution, a preparation method and application thereof. The traditional Chinese medicine compound Tenghuanglin comprises the following ingredients in parts: 80-100 parts of acanthopanax, 50-70 parts of semen cuscutae, 16-20 parts of schisandra chinensis, 40-50 parts of glossy privet fruit, 25-30 parts of polygonum cuspidatum, 50-70 parts of oldenlandia diffusa, 40-50 parts of astragalus mongholicus, 50-70 parts of codonopsis pilosula, 40-50 parts of barbary wolfberry fruit and 80-100 parts of caulis spatholobi. Experiment proves that the Tenghuanglin (THL) has the improvement effect on the multisystem damage of the organism induced by the microwave irradiation, the drug efficiency of the medicine is superior to that of the positive drug group (ADL), the clinic application amount is about one tenth of ADL, and the administration safety is obviously improved. The traditional Chinese medicine compound Tenghuanglin can be used for preventing and treating acute and chronic long-term microwave irradiation damage.

The invention provides a dynamic drug pot pre-grouping method for a fully-automatic Chinese medicine particle dispensing system. A drug pot rack (1), a guide rail (2), medicine pots (3), and a transposition mechanism (4) are arranged. The dynamic pre-grouping method comprises: step one, analyzing a to-be-processed prescription; step two, according to previous prescriptions, carrying out optimization based a genetic algorithm or carrying out continuous iteration based on an artificial intelligence algorithm, and selecting a drug group having the maximum sub set as a target group; step three, keeping a backbone drug that is determined by the algorithm and represents features of the group in the target group; step four, matching the prescription with the target group to determine a non-backbone drug; and step five, with the transposition mechanism, transferring the non-backbone drug that is not included by the target group in the prescription into the target group to complete drug dispersing. Therefore, the drug output part is reduced; the successive drug output speed is high; the stability is high; and the efficiency of the Chinese medicine particle dispensing system based on the traditional Chinese prescription is improved substantially.

The invention discloses a pharmaceutical composition for improving fluorouracil sensitivity. The pharmaceutical composition is characterized in that the pharmaceutical composition comprises fluorouracil and hydroxychloroquine linolenate, wherein the concentration of fluorouracil is 1.25 to 10 [mu] mol / L, and the concentration of hydroxychloroquine linolenate is 10 to 160 [mu] mol / L; a fluorouracilsingle-drug group, a hydroxychloroquine linolenate single-drug group and a fluorouracil combined hydroxychloroquine linolenate group are arranged; each group of experiments is independently repeatedfor three times; tumor cells are added and then are cultured on a micro-culture plate for 24 hours, 48 hours and 72 hours respectively; and data of the tumor cells are observed and recorded. The invention further discloses an application of the pharmaceutical composition for improving fluorouracil sensitivity in colorectal cancer. The pharmaceutical composition has the advantages that fluorouraciland hydroxychloroquine linolenate are combined for use, so that the chemosensitivity of fluorouracil can be improved, and the treatment effect is improved; the medication compliance of colorectal cancer patients can be improved; and meanwhile, the pain of the patients can be relieved.

The invention discloses a preparation technology and medical applications of a compound specific transfer factor. By adopting nanotechnology and chemical technology method, pathogenic virus, bacteria, parasites, and various tumors are prepared into split vaccines or subunit vaccines, which can prevent infectious diseases of human and livestock, according to the requirements on biological products. Then the vaccines are prepared into specific immunity antigens for animals by taking the fat emulsion as the auxiliary materials. Various animals are injected with the immunity antigens, the antibody levels, which are generated by the corresponding antigens, of the immunity animals are measured during the period. After the antibody levels meet the requirements, the animals qualified are immunized. The preparation technology comprises following steps: grinding the immunized organ tissues with a meat grinder, adding normal saline, filtering with a filtration pump, then processing the materials with a nano technology, and finally subjecting the materials to an ultra-filtration treatment so as to obtain the compound specific transfer factor. The specific transfer factor has the advantages of stable activity, high yield and large scale, the anti-septic disease spectrum is wide, the technology method is advanced, and the product quality is stable. The resources are fully utilized, and the production cost is largely reduced. Different user needs can be fully satisfied; the production period of the product is short, thus the work efficiency is largely improved; the drug group can be prepared into various dosage forms, and the product is user-friendly.

The present invention relates to a method and a system for selecting a drug customized on the basis of individual protein information by using individual genome sequences. The method and the system of the present invention can predict the individual side effects or danger of a certain drug by analyzing the sequence of the exon region of a gene encoding various proteins involved in the pharmacokinetics or pharmacodynamics of a predetermined drug or drug group, and have high reliability and are widely applicable and universal.

The invention relates to the technical field of medicines, provides use of an oncolytic virus VG161 in preparation of drugs for treating pancreatic cancer and further provides use of combination of the oncolytic virus VG161, gemcitabine and albumin paclitaxel in preparation of a drug group for treating the pancreatic cancer. Further, the invention further provides a pharmaceutical composition for treating the pancreatic cancer. The pharmaceutical composition is prepared from the oncolytic virus VG161 and a pharmaceutically-acceptable adjuvant. The invention simultaneously provides the drug group for treating the pancreatic cancer. The drug group comprises a forward drug and a subsequent drug, wherein the forward drug is prepared from the oncolytic virus VG161 and a pharmaceutically-acceptable adjuvant, and the subsequent drug is prepared from the gemcitabine and the albumin paclitaxel. Proven by in-vitro cell tests, the single VG161 can be used for effectively killing pancreatic cancer cells; and proven by mouse in-vivo experiments, the single VG161 can be used for effectively treating a transplanted tumor in a mouse model suffering from the pancreatic cancer. By employing combination of the VG161 and a GEM+Nab-PTX scheme, the treatment effect is further improved.

Provided is an anticancer compound including a cleavable linker specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is represented by the following formula, wherein, R1 is a normal functional group or a protection group; R2 is Ala, Thr, Val or Ile; R3 is Ala, Val or Asn; R4 is a drug group linked via a hydroxyl group or an amino group; and the general formula of the drug is R4H. The anticancer compound is only activated at a local portion of a tumor, thus avoiding the defect of immune system damage of a traditional chemotherapeutic drug, and promoting tumor immunization by removing a tumor immunosuppression cell. The anticancer compound or pharmaceutical composition thereof is jointly used with immunotherapy, thus improving the effect of treating the tumor, and effectively inhibiting tumor metastasis and osseous metastasis.